Pfizer completes licensing agreement with 3SBio to expand oncology portfolio
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
Revvity launches its first set of IVD Mimix reference standards, providing diagnostic labs with trusted quality controls for optimizing tests and monitoring workflows
The newly inaugurated facility bridges this gap by offering metro-grade treatment closer to home
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
SPARC to receive 55% equity in Tiller Therapeutics
Harnessing advanced data analysis for early detection, prevention and better outcomes
Subscribe To Our Newsletter & Stay Updated